Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYLIN-02: SHR-8068 + Adebrelimab + Bevacizumab in Advanced HCC
NCT06618664Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of CS1002 in hepatocellular carcinoma (HCC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Oct 2024; status: recruiting.
02
Drugs
CS1002
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06618664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618664.